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Abstract
Background—Women with a history of false-positive mammogram result may be at increased 
risk of developing subsequent breast cancer.
Methods—Using 1994 to 2009 Breast Cancer Surveillance Consortium data we included women 
ages 40–74 years with a screening mammogram that resulted in a false-positive with 
recommendation for additional imaging, false-positive with recommendation for biopsy, or true-
negative with no cancer within one year following the examination. We used partly conditional 
Cox proportional hazards survival models to assess the association between a false-positive 
mammogram result and subsequent breast cancer, adjusting for potential confounders. Adjusted 
survival curves stratified by breast density and false-positive result were used to evaluate changes 
in risk over time.
Results—During 12,022,560 person-years of follow-up, 48,735 cancers were diagnosed. 
Compared to women with a true-negative examination, women with a false-positive with 
additional imaging recommendation had increased risk of developing breast cancer (adjusted 
hazard ratio (aHR)=1.39, 95%CI:1.35–1.44) as did women with a false-positive with a biopsy 
recommendation (aHR=1.76, 95%CI:1.65–1.88). Results stratifying by breast density were similar 
to overall results except among women with almost entirely fatty breasts in which aHRs were 
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similar for both false-positive groups. Women with a false-positive result had persistently 
increased risk of developing breast cancer 10-years after the false-positive examination.
Conclusion/Impact—Women with a history of a false-positive screening mammogram or 
biopsy recommendation were at increased risk of developing breast cancer for at least a decade, 
suggesting that prior false-positive screening may be useful in risk prediction models.
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Introduction
In the United States an estimated 67% of women ages 40 and older undergo screening 
mammography every 1–2 years (1). Among these screening examinations, approximately 
16% of first and 10% of subsequent mammograms will generate a false-positive result (2). 
Over the course of ten screening mammograms, the estimated cumulative probability of at 
least one false-positive result is 61% for women screened annually and 42% for women 
screening biennially (2).
Prior studies examining the risk of breast cancer among women with a history of a false-
positive screening mammogram report conflicting findings (3–8). The majority of these 
studies were conducted in Europe where false-positive rates are substantially lower than in 
the United States (9–10). The one study conducted in the United States found that a false-
positive result was predictive of future breast cancer risk among postmenopausal but not 
premenopausal women (6). Although breast density is a strong risk factor for breast cancer 
and is also associated with elevated false-positive rates (11), no previous study has 
examined whether a false-positive result influences the risk of developing breast cancer 
differently for those with non-dense vs. dense breasts. Given that false-positives are 
common in the U.S., the attributable risk associated with false-positive examinations could 
be substantial if the association with breast cancer is strong.
Our study sought to extend current knowledge by examining whether the relationship 
between history of a false-positive screening mammogram result and the risk of developing 
breast cancer varies according to the type of recommendation associated with false-positive 
results or by mammographic breast density. Using data from the Breast Cancer Surveillance 
Consortium (BCSC) from 1994 to 2009 from seven registries, we evaluated the association 
between false-positive mammograms with differing follow-up recommendations (either 
workup with imaging alone or workup involving biopsy) and breast cancer risk overall and 
stratified by breast density. We hypothesized that there would be a greater increase in breast 
cancer risk among women with a history of false-positive biopsy recommendation results 
compared to those with a false-positive additional imaging recommendation and that this 
association would be independent of breast density.
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We utilized data from the BCSC, which are representative of the US population (12). 
Specifically, we included data from seven registries located in New Hampshire, North 
Carolina, San Francisco Bay Area, Western Washington state, New Mexico, Colorado and 
Vermont. Details on the BCSC have been described previously (13). Briefly, at each registry 
prospective data collection includes self-reported demographic characteristics, indication for 
mammogram, breast cancer risk factors, Breast Imaging Reporting and Data Systems (BI-
RADS) mammography assessment and breast density (14), and the radiologists’ 
management recommendations. The patient and mammography data are linked with 
pathology databases and state cancer registry data to obtain information on subsequent 
cancer diagnoses. Data from each registry are sent to a central Statistical Coordinating 
Center for quality control and pooled analyses. Each registry and the Statistical Coordinating 
Center received institutional review board approval for either active or passive consent or a 
waiver of consent to enroll participants, link study data, and perform analytic studies. All 
procedures are Health Insurance Portability and Accountability Act compliant and all 
registries as well as the Statistical Coordinating Center have received a Federal Certificate of 
Confidentiality.
Study Population
We included screening mammograms received by women ages 40 to 74 years performed 
between 1994 and 2009. We excluded women with a prior breast cancer diagnosis and 
women who lacked complete information on age, race/ethnicity, family history of breast 
cancer, history of breast biopsy, or BI-RADS breast density. From pathology and cancer 
registry data we classified women as having incident breast cancer if a diagnosis of invasive 
carcinoma or ductal carcinoma in situ occurred (Figure 1).
Measures and Definitions
At each mammography examination, women completed a questionnaire on demographic and 
breast health history. Women self-reported race and ethnicity and were categorized as non-
Hispanic white, non-Hispanic black, Hispanic, Asian/Native Hawaiian/Pacific Islander, 
Native American/Native Alaskan, or other. Women were categorized as having a family 
history of breast cancer if they had at least one first-degree relative with the disease, 
irrespective of the age of the relative at the time of diagnosis. The time since prior 
mammography was determined using information from the radiology practice or self-
reported information from the woman. History of a breast biopsy was ascertained from both 
pathology records and self-report. Mammographic breast density was assessed by the 
radiologist interpreting the screening mammogram using the BI-RADS breast density 
categories of almost entirely fat, scattered fibroglandular densities, heterogeneously dense, 
and extremely dense (14).
Each index screening mammogram was classified as false-positive, true-negative, false-
negative, or true-positive based on (1) the radiologists’ interpretation using the BI-RADS 
lexicon and (2) if breast cancer was diagnosed within one year of the screening 
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mammogram (Figure 2). Positive assessments were defined as those with an initial BI-
RADS assessment of 0, 4, 5, or 3 when accompanied by a recommendation for immediate 
evaluation. Screening mammograms with a positive assessment and no cancer diagnosis in 
the following one-year were classified as false-positive examinations. Negative assessments 
were defined as those with a BI-RADS assessment of 1, 2, or 3 if not accompanied by a 
recommendation for immediate evaluation. Mammograms with a negative assessment and 
no cancer diagnosis within one year were classified as true-negative examinations. 
Screening mammograms with positive assessment and cancer diagnosis within one-year 
were classified as true-positive. Screening mammograms with a negative assessment and a 
cancer diagnosis within one-year were classified as false-negative examinations. We 
excluded true-positive or false-negative mammograms, as cancers associated with these 
examinations were assumed to have been present at the time of the screening mammogram 
and our study focused on cancers diagnosed subsequent to the index screening examination.
Follow-up for breast cancer diagnosis began one year after each index screening 
mammogram and continued for ten years or through the end of 2011, whichever occurred 
first (Figure 2). Since we were interested in comparing the risk of breast cancer among 
women with and without a false positive result, we included screening examinations 
performed through 2009 to allow for a minimum of one year to determine if the screening 
exam resulted in a false-positive and another year to follow women for breast cancer 
diagnosis.
Among screening examinations with a false-positive result, we subdivided mammograms, 
based on the radiologists’ BI-RADS assessment and recommendations following the BI-
RADS 4th edition atlas, as those with a recommendation for additional imaging only and 
those with a recommendation for biopsy. Mammograms with a final BI-RADS assessment at 
the end of all imaging evaluation of 4, 5, or 0 or 3 when accompanied by a recommendation 
for biopsy or surgical consultation were classified as false-positive biopsy recommendations. 
All other false-positives were classified as false-positive imaging recommendations. Hence 
our interest was in comparing three groups of women: those with a false-positive result who 
were recommended for additional imaging only (false-positive with imaging 
recommendation), those with a false-positive result who were recommended for biopsy 
(false-positive with biopsy recommendation), and those with true-negative examinations.
Statistical Analysis
We compared demographics and risk factors of the 3 groups: false-positive with imaging 
recommendation, false-positive with biopsy recommendation, and true-negatives. We 
examined the number of breast cancer cases, the person-years (P-Y) at risk for developing 
breast cancer and the breast cancer rate overall and stratified by the four BI-RADS breast 
density categories. Exact Poisson confidence intervals are provided for breast cancer rates.
To determine if women with a history of a false-positive versus a true-negative screening 
result were more likely to continue to be screened and thus may appear to have higher 
cancer rates, we computed the proportion of women in each group (true-negative and false-
positive) who received subsequent screening mammograms.
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We used a partly conditional Cox proportional hazard survival model to assess the 
association between a false-positive mammography result (with additional imaging or with 
biopsy recommendation separately) and breast cancer (15). By using the partly conditional 
Cox model, we were able to include all mammograms received by an individual woman 
while accounting for within-woman correlation. In these analyses, the mammogram was the 
unit of analysis. Each false-positive or true-negative mammogram initiated a new follow-up 
period, which continued until the first of breast cancer diagnosis or censoring by death, end 
of health plan enrollment (for women in the Western Washington state registry), ten years of 
follow-up, or the end of the study period. All models were adjusted for age, race/ethnicity, 
menopausal status, breast density, history of breast biopsy, time since prior mammogram, 
and family history of breast cancer. We investigated models with three levels of interaction 
between density and false-positive mammography results. First, we included only main 
effects of density and false-positive results without interaction terms. This model assumed 
that the association between false-positive results and survival was the same for all densities. 
Next we added the interaction between false-positive results and breast density to investigate 
possible differential effects of false-positive results for women with different breast 
densities. Finally, we fit a model with baseline hazards stratified by breast density and false-
positive results to investigate possible time-varying relationships between false-positive 
groups for each breast density group. Hence, adjusted hazard ratios and 95% confidence 
intervals (CI) for false-positive results are reported (1) overall and (2) separately by breast 
density based on the interaction model. Results of models with stratified baseline hazards 
based on density and false-positive results are presented graphically, with follow-up 
beginning at 12 months after the screening mammogram, in the form of adjusted survival 
curves since no single hazard ratio represents the effect of false-positive results for these 
models. The proportional hazards assumption was assessed by testing for a statistically 
significant interaction between the covariate and log time. This test found no evidence of 
violation of the proportional hazards assumption.
All analyses were conducted using R version 2.15.3 (R Foundation for Statistical 
Computing, Vienna, Austria).
Results
The study population included 2,207,942 screening mammograms performed in 1,297,906 
women. The highest proportion of false-positive examinations with recommendations for 
additional imaging or biopsy occurred among women ages 40–49 years (34.8% and 33.1%, 
respectively) (Table 1). False-positive results were also common among pre-menopausal 
women. A higher proportion of false-positive examinations were present among women 
with heterogeneously or extremely dense breasts compared to women with almost entirely 
fat breasts or scattered fibroglandular densities.
For those with a true-negative result, the total P-Y at risk for developing a breast cancer after 
the screening examination was 11,034,496 P-Y with a total of 43,105 breast cancers 
occurring during this time period (Table 2), giving a breast cancer rate per 1000 P-Y of 3.91 
(95%CI: 3.87, 3.94). Among those false-positives with imaging recommendation, the breast 
cancer rate per 1000 P-Y was 5.51 (95%CI: 5.35, 5.66). In false-positives with a biopsy 
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recommendation, the breast cancer rate per 1,000 P-Y was 7.01 (95%CI: 6.56, 7.48). Breast 
cancer rates stratified by BI-RADS breast density showed similar patterns with cancer rates 
highest for false-positives with a biopsy recommendation and lowest for those with true-
negative results for women with scattered fibroglandular densities, heterogeneously dense, 
or extremely dense breasts. In the almost entirely fat group, the breast cancer rates were 
similar regardless of false-positive recommendation type (3.69 with 95%CI: 3.07, 4.41 for 
false-positive with an imaging recommendation versus 3.98 with 95%CI: 2.53, 5.97, for 
false-positives with a biopsy recommendation).
During one year of follow-up, 19.2% of women with a false-positive result and 21.0% of 
women with a true negative result received a subsequent screening mammogram. The 
proportion with a screening mammogram in the two groups are similar at 2, 3, 4 and 5 years 
of follow-up indicating that women with a false-positive are not more likely to be screened 
in the future compared to women with a true-negative.
In Cox proportional hazards models adjusted for age, race/ethnicity, history of benign breast 
biopsy, time since prior mammogram, and family history of breast cancer, the comparison of 
those with a false-positive result to those with a true-negative result are shown in Table 3, 
overall and allowing for an interaction between breast density and false-positive results. The 
adjusted hazard ratio for women with a screening mammogram with a false-positive result 
with an imaging recommendation was 1.39 relative to women with a true-negative result. 
Among women with a screening mammogram with a false-positive result with a biopsy 
recommendation, the adjusted hazard ratio was 1.76 relative to women with a true-negative 
result. In those women with almost entirely fatty breasts, the adjusted hazard ratio 
comparing those with a false-positive imaging recommendation to those with a true-negative 
result is 1.70 and comparing those with a false-positive biopsy recommendation to those 
with a true-negative result is 1.77. Among those with scattered fibroglandular densities, 
heterogeneously dense, and extremely dense breasts, having a false-positive imaging 
recommendation had an increased hazard of 34–44% and having a false-positive biopsy 
recommendation had 74–87% higher hazard (all p-values<0.01).
To determine if the increased risk of developing breast cancer among those with a false-
positive result changed over time we examined survival curves stratified by breast density 
and false-positive results (Figure 3). In Figure 3, the follow-up time begins 12 months after 
the index mammogram. Among women with almost entirely fat breasts (Figure 3A) the 
probability of remaining breast cancer free for women with a true-negative result at 60 
months is 99% compared with 98% for both of the false-positive groups. Both of the false-
positive groups appear to have similar survival based on Figure 2A indicating a similar risk 
of developing breast cancer and a risk that continues to be slightly higher than that of the 
true-negative group as far out as 120 months (10 years). For those with scattered 
fibroglandular densities, the survival plot (Figure 3B) shows a similar risk for the two false-
positive groups up to 24 months and then these two groups begin to diverge with the false-
positive biopsy recommendation having the higher risk of developing breast cancer. For 
those with heterogeneously dense breasts, the risk of developing breast cancer among the 
false-positive groups diverge after 24 months and there is an increased risk as evidenced by 
the steeper lines (Figure 3C). Among those with extremely dense breasts, the risk of 
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developing breast cancer differs among the 3 groups at 12 months and continues to diverge 
over time (Figure 3D).
Discussion
We found that women with a history of a false-positive screening mammogram result were 
at increased risk of developing breast cancer with those recommended for additional 
imaging having a 39% higher hazard and those recommended for biopsy having a 76% 
higher hazard compared to women with a true-negative mammogram result. Stratification by 
breast density revealed similar results for women with scattered fibroglandular, 
heterogeneously dense and extremely dense breast tissue; however among women with 
almost entirely fatty breasts, both false-positive groups had about a 70% higher hazard 
compared to women with a true-negative mammogram result. We also found that women 
with a history of a false-positive result continued to have an increased risk of developing 
breast cancer 10-years after experiencing the false-positive result.
Our findings are consistent with several studies. A 2012 study from Denmark examined the 
long-term risk of breast cancer and found a 67% increased risk among women with a prior 
false-positive result (7). More recently, data from a population-based breast cancer screening 
program in Spain reported that false-positive results involving fine needle aspiration 
cytology or a biopsy had a higher subsequent cancer detection risk than those false-positive 
results involving additional imaging procedures alone (8). A study from the United 
Kingdom found that women with a false-positive result on their first screening mammogram 
had a higher interval cancer rate than women with true-negative results (5). Barlow’s BCSC 
paper from 2006 (6) included prior false-positive mammogram in one-year risk models and 
found that in multivariate models, prior false-positive was associated with increased risk for 
postmenopausal, but not premenopausal women. However, Barlow et al. used strict criteria 
(p-value <0.0001) for determining which patient factors to include in the breast cancer risk 
prediction model, and in the premenopausal model, the variable indicating the result of the 
previous mammogram had a p-value of 0.0018 (6). We examined our results stratified by 
menopausal status and found that the HR for the false-positive recommendations were 
similar by menopausal status [comparing false-positive with additional imaging to true 
negative for premenopausal HR=1.32 (95%CI: 1.25–1.39) versus for postmenopausal 
HR=1.43 (95%CI: 1.38–1.48); comparing false positive with biopsy to true-negative for 
premenopausal HR=1.69 (95%CI: 1.49–1.91) versus for postmenopausal HR=1.78 (95%CI: 
1.64–1.92)]. In contrast to other studies (5–8), two small studies from the Netherlands 
reported no excess breast cancer risk among women with a prior false-positive compared to 
women with no history of a false-positive (3, 4).
No prior studies assessed differences in breast cancer risk among women with a false-
positive result stratified by breast density. The increase in risk we observed among women 
with false-positive imaging and biopsy recommendations was similar across density groups, 
with the exception of the almost entirely fat group. Notably, the absolute risk of breast 
cancer is higher for women with dense breast tissue. Thus, the highest risk of breast cancer 
observed in our study was among women with extremely dense breasts who had false-
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positive results with a biopsy recommendation. Among women with fatty breasts, the 
absolute risk of breast cancer remained relatively low for both type false-positives groups.
Our finding that breast cancer risk remains elevated up to 10 years after the false-positive 
result suggests that the radiologist observed suspicious findings on mammograms that are a 
marker of future cancer risk. Given that the initial result is a false-positive, it is possible that 
the abnormal pattern while noncancerous, is a radiographic marker associated with 
subsequent cancer. About 30% of benign breast biopsies are found to have proliferative 
changes with or without atypia (16). Thus, these proliferative changes could account, in part, 
for the increased risk associated with false-positives results with a recommendation for 
biopsy.
We investigated the possibility of ascertainment bias using the BCSC data to compute the 
proportion of women in each group (true negative and false-positive) who received 
subsequent screening mammograms. While this does not provide the actual rate of screening 
since some women may have undergone mammography outside BCSC catchment areas, we 
can compare the proportions between groups to see if women with false-positives obtained 
more screening within in the BCSC than true-negatives. Given that the proportion of women 
with a screening mammogram in the true negative and false positive groups is similar we 
find no evidence of differential ascertainment of cancer due to more frequent screening.
The current BCSC breast cancer risk prediction model includes age, race/ethnicity, first-
degree relatives with breast cancer, history of breast biopsy, and BI-RADS breast density 
(17). This model is well calibrated in major race and ethnic groups in the US and has modest 
discriminatory accuracy to discern between women who will and will not develop breast 
cancer (concordance index=0.66). Given that the survival curves show persistent increases 
in risk over time and the fact that the increased risk associated with history of a false-
positive is independent of breast density and history of breast biopsy, the inclusion of a prior 
false-positive results may improve risk prediction in the BCSC model.
Strengths of our study include the large sample size, prospective observation and the ability 
to follow women for an average of 5.4 years for cancer outcomes. We also were able to 
include multiple mammography results per woman over time, which increased the statistical 
power to detect differences by density category. The study population is racially and 
geographically diverse, with the majority of the examinations coming from community 
practice. Breast density was assessed using the BI-RADS classification and could be 
misclassified given the modest inter-rater agreement known to exist, but this is unlikely to 
affect the results given the similar hazard ratios for density categories (18, 19).
Our study also has several limitations. Women may have moved out of our study catchment 
area and thus we may miss some breast cancer diagnoses; however, we do not expect that 
this potential loss to follow-up would differ for women with a false-positive versus true-
negative result. In addition, we excluded women with missing covariates, which could bias 
our findings if missingness was not at random. We believe missing values are unrelated to 
patient or mammogram characteristics since missing values most often arose because a 
mammography facility did not collect the covariate information during the time when a 
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woman received her mammogram. Since these missing values arose structurally, they are 
not expected to be associated with patient characteristics and thus will not introduce bias. 
Another limitation is that data on laterality of the mammographic lesion was not available 
and thus we are unable to assess how many cancers developed at the site of the initial 
mammographic lesion and how many were missed cancers.
In conclusion, women with a false-positive screening mammogram result are at increased 
risk for developing breast cancer, with a higher risk for false-positives with a 
recommendation for biopsy compared with additional imaging recommendation. The risk 
was independent of breast density and remained elevated for a decade after receipt of the 
false-positive result. This information should be considered for inclusion in risk prediction 
models to better stratify women into risk categories that may be used to personalize breast 
cancer screening and primary prevention strategies for individual women.
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Figure 1. Flowchart of Study Population
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Figure 2. Study Design
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Figure 3. Adjusted survival curves for breast cancer based on Cox proportional hazards model 
with baseline hazards stratified by breast density and screening mammogram result
Models adjusted for age, race/ethnicity, menopausal status, history of breast biopsy, and 
family history of breast cancer. Solid black line represents true negative screening 
mammogram result group; Dotted black line represents false positive with additional 
imaging recommendation group; Dashed black line represents false positive with biopsy 
recommendation group. Each breast density group is represented in panels A-D where A: 
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Almost entirely fat; B: Scattered fibroglandular densities; C: Heterogenously dense; D: 
Extremely dense.
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Table 2









(95%CI) per 1000 P-Y
ALL WOMEN:
  True-negative 43,105 11,034,496 3.91 (3.87, 3.94)
  False-positive, additional imaging 4,742 861,365 5.51 (5.35, 5.66)
  False-positive, biopsy 888 126,699 7.01 (6.56, 7.48)
BY BI-RADS BREAST DENSITY:
ALMOST ENTIRELY FAT
  True-negative 2,206 993,559 2.22 (2.13, 2.31)
  False-positive, additional imaging 123 33,291 3.69 (3.07, 4.41)
  False-positive, biopsy 23 5,774 3.98 (2.53, 5.97)
SCATTERED FIBROGLANDULAR DENSITY
  True-negative 17,884 5,070,911 3.53 (3.37, 3.47)
  False-positive, additional imaging 1,737 355,192 4.89 (4.51, 4.95)
  False-positive, biopsy 315 52,612 5.99 (5.09, 6.36)
HETEROGENEOUSLY DENSE
  True-negative 19,014 4,143,830 4.59 (4.52, 4.65)
  False-positive, additional imaging 2,372 398,280 5.96 (5.72, 6.20)
  False-positive, biopsy 448 56,984 7.86 (7.15, 8.62)
EXTREMELY DENSE
  True-negative 4,001 826,197 4.84 (4.69, 4.99)
  False-positive, additional imaging 510 74,602 6.84 (6.26, 7.45)
  False-positive, biopsy 102 11,329 9.00 (7.35, 10.92)
BI-RADS = Breast Imaging-Reporting and Data System; CI = confidence interval; P-Y = person years
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